Vincristine combination with Ca+2 channel blocker increase antitumor effects

[1]  Naldan Muhammet Emin.  Should we use remifentanil in every dose and every case? , 2019, Journal of Clinical and Analytical Medicine.

[2]  A. Dolphin.  Voltage-gated calcium channels: Their discovery, function and importance as drug targets , 2018, Brain and neuroscience advances.

[3]  Larissa F Carvalho,et al.  The use of antioxidant agents for chemotherapy‐induced peripheral neuropathy treatment in animal models , 2017, Clinical and experimental pharmacology & physiology.

[4]  N. Ratner,et al.  The “neuro” of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder , 2016, Annals of neurology.

[5]  A. Dolphin,et al.  The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential , 2015, Pharmacological Reviews.

[6]  M. Stiborová,et al.  The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. , 2015, International journal of oncology.

[7]  L. Ferrari,et al.  Arterial hypertension and cancer , 2014, International journal of cancer.

[8]  C. Dominici,et al.  Long-term Follow-up of the “Wait and See” Approach to Localized Perinatal Adrenal Neuroblastoma , 2013, World Journal of Surgery.

[9]  Z. Erbayraktar,et al.  The role of p14ARF methylation in neuroblastoma minimal residual disease , 2012 .

[10]  S. Aktaş,et al.  The role of p 14 ARF methylation in neuroblastoma minimal residual disease [ Nöroblastom ’ da p 14 ARF metilasyonunun minimal rezidüel hastalıktaki rolü , 2012 .

[11]  M. Stiborová,et al.  Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells. , 2012, Neuro endocrinology letters.

[12]  Yan Zhang,et al.  Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. , 2011, Molecular pharmaceutics.

[13]  S. Kjeldsen,et al.  Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. , 2011, The Lancet. Oncology.

[14]  S. Nissen.  Angiotensin-receptor blockers and cancer: urgent regulatory review needed. , 2010, The Lancet. Oncology.

[15]  D. Rowland,et al.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. , 2010, The Lancet. Oncology.

[16]  Y. Aksoy.  Kanserde İlaç Direncinin Üstesinden Gelmenin Yolları: Yeni İlaçların Tasarımı , 2010 .

[17]  F. Stevenson,et al.  A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose , 2008, Journal of Medical Toxicology.

[18]  Supradip Ghosh,et al.  A rare malposition of the thoracic venous catheter introduced via the left internal jugular vein , 2008, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[19]  Supradip Ghosh,et al.  Calcium channel blocker overdose: Experience with amlodipine , 2008, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[20]  L. Moretta,et al.  Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule , 2008, Histopathology.

[21]  M. Kars.  Molecular mechanisms of vincristine and paclitaxel resistance in mcf-7 cell line. , 2008 .

[22]  M. Pahor,et al.  Trends of the characteristics and appropriateness of admissions to acute geriatric and medical wards in Italy from 1988 through 1993 , 1996, European Journal of Epidemiology.

[23]  Y. Pommier,et al.  Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.

[24]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[25]  D. Abernethy,et al.  Calcium-antagonist drugs. , 1999, The New England journal of medicine.

[26]  N. Karnik,et al.  Amlodipine in mild and moderate hypertension: initial Indian experience. , 1993, The Journal of the Association of Physicians of India.

[27]  P. Alken,et al.  Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. , 1990, Cancer research.

[28]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .

[29]  M. Materazzi,et al.  Effects of a calcium-antagonist (flunarizine) on cancer cell movement and phagocytosis. , 1985, Anticancer research.

[30]  H. Tritthart,et al.  [A new group of competitive divalent Ca-antagonists (iproveratril, D 600, prenylamine) with potent inhibitory effects on electromechanical coupling in mammalian myocardium]. , 1969, Pflugers Archiv : European journal of physiology.